Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer

  • Genentech, a unit of Roche Holdings AG (OTC:RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). 
  • The trial evaluated tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment in 534 NSCLC patients. 
  • The study did not meet its co-primary endpoint of progression-free survival. 
  • At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis. 
  • Also See: Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial.
  • A numerical improvement was observed in both co-primary endpoints. 
  • Data suggest that tiragolumab plus Tecentriq was well-tolerated, and no new safety signals were identified when adding tiragolumab. 
  • Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. It selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.